|Bid||0.00 x 1100|
|Ask||37.68 x 900|
|Day's Range||37.71 - 41.85|
|52 Week Range||7.41 - 61.59|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||54.60|
The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.
What happened Shares of Invitae (NYSE: NVTA) had fallen 6.6% as of 3:13 p.m. EST on Wednesday. The medical genetics company didn't announce any news that would cause the stock to drop. Instead, Invitae's decline today appears to be part of a broader sell-off of high-growth stocks, with the Nasdaq Composite Index falling 2%.
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, in collaboration with Invitae Corporation (NYSE: NVTA, "Invitae"), a leading medical genetics company, announces the launch of a sponsored genetic testing program, navigateAPDS, designed to assist clinicians in identifying patients and their family members with activated PI3K delta syndrome (APDS), which may lead to earlier diagnosis.